Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy MarketWatch (press release) We have seen positive results in clinical trials combining our anti-CD22 antibody, epratuzumab, with the anti-CD20 antibody, rituximab. With the recent unencumbered return of the oncology indication for epratuzumab, new opportunities for licensing of ... |
